Brief: BioXcel Therapeutics Q4 Basic EPS USD -0.58 Vs. IBES Estimate USD -0.75
27/03/2026 11:00
Mar 27 (Reuters) - BioXcel Therapeutics Q4 revenue USD 256 thousand vs. IBES estimate USD 162 thousand. Q4 operating income USD -10.282 million vs. IBES estimate USD -11.7 million Q4 operating expenses USD 10.538 million Q4 net income USD -12.545 million vs. IBES estimate USD -14.4 million
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty